Dizal Pharmaceutical Hits Day High with 10.69% Surge Amid Market Decline

Dizal (Jiangsu) Pharmaceutical Co., Ltd. has experienced a significant surge in its stock price, gaining 10.69% on May 21, 2026. The stock reached an intraday high of CNY 60.74, marking a notable performance against the backdrop of the China Shanghai Composite, which declined by 2.04% on the same day. Over the past week, Dizal has shown a positive trend with a 4.45% increase, while its monthly performance stands at 3.3%. However, the company's one-year performance reflects a modest gain of 1.57%, underperforming the broader market, which has seen a return of 20.36% during the same period. Despite the recent uptick, Dizal faces challenges, including a low Return on Capital Employed (ROCE) of 18.72% and a high Debt to Equity ratio, indicating potential concerns regarding profitability and financial stability. The company has reported negative returns on equity and has struggled with operating profit growth over the past five years. As a large-cap player in the miscellaneous industry, Dizal's market capitalization stands at CNY 24,168 million.